First-in-class phosphate absorption inhibitor approved by FDA
European Pharmaceutical Review
OCTOBER 18, 2023
However, in the trials, the only observed adverse reaction for the treatment was diarrhoea. Further to the three Phase III trials for XPHOZAH, Ardelyx also declared that it has completed two open-label clinical trials (OPTIMIZE and NORMALIZE) to evaluate different options for integrating the treatment into clinical practice.
Let's personalize your content